NEW YORK and WALTHAM, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional ...

Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

Multifocal motor neuropathy is a rare autoimmune disorder that develops when the immune system over actively creates antibodies that attack healthy cells and cause damage to a particular part of the ...

Multifocal Motor Neuropathy (MMN) is a rare condition in which multiple motor nerves are attacked by one’s immune system. This attack causes weakness of muscles but not loss of sensation. The ...

A scientific team supported by the National Institutes of Health has created a tiny, bioengineered 3-D model that mimics the biology of chronic inflammatory demyelinating polyneuropathy and multifocal ...

Baxter International Inc. (NYSE:BAX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension ...

June 27, 2012 — Immune Globulin Infusion (Human), 10% (Gammagard Liquid, Baxter International, Inc), has been approved by the US Food and Drug Administration (FDA) as a treatment for multifocal motor ...

Kieseier and colleagues present a review of the literature on immune-mediated neuropathies, emphasizing the immunopathologic mechanisms underlying these neuropathies. Immune-mediated neuropathies have ...

Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) in 1Q’24 and planned initiation of a Phase 2 trial in Chronic ...